166 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
10
Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.
Goethe-University Frankfurt
13
Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists.
Peking Union Medical College
24
Discovery and optimization of benzimidazole derivatives as a novel chemotype of farnesoid X receptor (FXR) antagonists.
Hiroshima International University
2
Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
Beckman Research Institute
28
Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties.
Phenex Pharmaceuticals
2
Novel approaches to map small molecule-target interactions.
Max Planck Institute of Molecular Physiology
4
The Halicylindramides, Farnesoid X Receptor Antagonizing Depsipeptides from a Petrosia sp. Marine Sponge Collected in Korea.
Daegu-Gyeongbuk Medical Innovation Foundation
14
Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist.
Zydus Research Centre
28
SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious ROR¿ Inhibitor.
Central Pharmaceutical Research Institute
3
Altered activity profile of a tertiary silanol analog of multi-targeting nuclear receptor modulator T0901317.
The University of Tokyo
24
Identification of N-sulfonyl-tetrahydroquinolines as RORc inverse agonists.
Genentech
40
Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists.
East China University of Science and Technology
29
Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.
Genentech
44
Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.
Goethe-University Frankfurt
12
Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
Goethe-University Frankfurt
27
Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of Action.
Genentech
27
Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonists.
Genentech
9
Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists.
Glaxosmithkline
20
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORß and ROR¿t.
Phenex Pharmaceuticals
38
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
Goethe-University Frankfurt
3
Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
University of Naples&Quot;Federico Ii&Quot
32
Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor.
Beckman Research Institute
12
Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).
Goethe-University Frankfurt
1
Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.
Istituto Italiano Di Tecnologia
22
Discovery and SAR study of hydroxyacetophenone derivatives as potent, non-steroidal farnesoid X receptor (FXR) antagonists.
East China University of Science and Technology
29
Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc.
Genentech
19
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
City of Hope National Medical Center
9
Asymmetric synthesis of the four diastereoisomers of a novel non-steroidal farnesoid X receptor (FXR) agonist: role of the chirality on the biological activity.
University of Perugia
3
Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands.
Istituto Italiano Di Tecnologia
17
Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists.
Pfizer
11
Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking.
East China University of Science and Technology
8
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
TBA
27
Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists.
University of Perugia
12
E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity.
The University of Tokyo
7
Tuberatolides, potent FXR antagonists from the Korean marine tunicate Botryllus tuberatus.
Seoul National University
3
Diversity-oriented synthesis: exploring the intersections between chemistry and biology.
Memorial Sloan-Kettering Cancer Center
56
Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes.
Universite Louis Pasteur
68
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
Centre National de la Recherche Scientifique/INSERM/ULP
6
Farnesoid X-activated receptor antagonists from a marine sponge Spongia sp.
Seoul National University
12
Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
University of Perugia
4
Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands.
University of Tokyo
2
Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study.
University of Perugia
17
Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
The Scripps Research Institute
6
Farnesoid X receptor: from structure to potential clinical applications.
University of Perugia
26
Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
University of Perugia
6
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.
TBA
11
Identification of a chemical tool for the orphan nuclear receptor FXR.
Glaxo Wellcome Research & Development
7
Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR).
University of Perugia
3
Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation.
University of Innsbruck
1
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
University of Innsbruck
15
Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene.
Glaxosmithkline
46
Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase type 1.
Vitae Pharmaceuticals
4
Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3a,7a-dihydroxy-6a-ethyl-24-nor-5β-cholan-23-amine.
University of Perugia
25
Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.
Glaxosmithkline
32
Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.
F. Hoffmann-La Roche
17
Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia& diabetes.
F. Hoffmann-La Roche
34
Discovery and optimization of adamantyl carbamate inhibitors of 11ß-HSD1.
Vitae Pharmaceuticals
30
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
Phenex Pharmaceuticals
32
Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates.
Wyeth Research
18
Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR).
Wyeth Research
23
FXR agonist activity of conformationally constrained analogs of GW 4064.
Glaxosmithkline
40
Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
Glaxosmithkline
48
Discovery of Highly Potent, Selective, and Liver-Targeting HSD17B13 Inhibitor with Robust In Vivo Anti-MASH Activity.
Guangdong Pharmaceutical University
70
Structure-Based Design and Optimization Lead to the Identification of a Novel Potent sEH Inhibitor with PPARγ Partial Agonist Activity against Inflammatory and Metabolic-Related Diseases.
Shenyang Pharmaceutical University
53
Discovery of First-in-Class FXR and HSD17B13 Dual Modulator for the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease.
Guangdong Pharmaceutical University
10
Dual Modulator of FXR and HSD17B13: Revitalizing FXR Therapies in MASH.
The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning
34
Design, synthesis, and biological evaluation of novel highly potent FXR agonists bearing piperidine scaffold.
Guangdong Pharmaceutical University
24
A Collection of Novel Antitumor Agents That Regulate Lipid Metabolism in the Tumor Microenvironment.
Shenyang Pharmaceutical University
30
Design, Synthesis, and Pharmacological Evaluation of Dual FXR-LIFR Modulators for the Treatment of Liver Fibrosis.
University of Naples "Federico II"
31
Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists.
Guangdong Pharmaceutical University
27
Nonlipogenic ABCA1 Inducers (NLAI) for Alzheimer's Disease Validated in a Mouse Model Expressing Human APOE3/APOE4.
University of Arizona
7
Scalarane sesterterpenes from a marine sponge of the genus Spongia and their FXR antagonistic activity.
Seoul National University
23
Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis.
Guilin Medical University
35
Discovery and Optimization of Novel Nonbile Acid FXR Agonists as Preclinical Candidates for the Treatment of Inflammatory Bowel Disease.
Nanjing University of Chinese Medicine
11
Discovery of novel and selective farnesoid X receptor antagonists through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation.
Peking University
2
The discovery of 12β-methyl-17-epi-18-nor-bile acids as potent and selective TGR5 agonists.
Victoria University of Wellington
4
Structural optimization and biological evaluation of 1-adamantylcarbonyl-4-phenylpiperazine derivatives as FXR agonists for NAFLD.
Chinese Academy of Medical Sciences&Peking Union Medical College
7
Discovery and development of palmatine analogues as anti-NASH agents by activating farnesoid X receptor (FXR).
Chinese Academy of Medical Sciences & Peking Union Medical College
1
Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes.
Guangdong Pharmaceutical University
27
Development of a Potent Nurr1 Agonist Tool for In Vivo Applications.
Ludwig Maximilian University of Munich
4
Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease.
Chinese Academy of Medical Sciences&Peking Union Medical College
26
Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis.
Hepagene Therapeutics
43
Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease.
Guangdong Pharmaceutical University
26
Chemical exploration of TGR5 functional hot-spots: Synthesis and structure-activity relationships of C7- and C23-Substituted cholic acid derivatives.
Tes Pharma
34
A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives.
China Pharmaceutical University
7
Development of 3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-sulfate sodium salt (INT-767): Process optimization, synthesis and characterization of metabolites.
University of Perugia
20
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment.
Sichuan University
61
Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases.
Eli Lilly
57
Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist.
Guangzhou Medical University
28
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.
Institute of Mit and Harvard
81
Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor.
University of Health Sciences and Pharmacy
29
Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio.
Nanchang University
27
Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist.
Shandong University
13
Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
Shandong University
16
Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis.
Southern Medical University Biomedical Research Center
33
Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis.
Biocon-Bristol Myers Squibb Research and Development Center
101
Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators.
Universidade De SãO Paulo
30
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
Chinese Academy of Sciences
28
Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics.
Goethe University Frankfurt
18
Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis.
Bristol Myers Squibb
47
Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist.
Guangdong Pharmaceutical University
2
Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure-activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism.
Computer-Aided Molecular Modeling Research Center
13
Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
China Pharmaceutical University
16
A New FXR Ligand Chemotype with Agonist/Antagonist Switch.
Goethe-University Frankfurt
40
Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
Chinese Academy of Sciences
8
Discovery of Orally Active and Nonsteroidal Farnesoid X Receptor (FXR) Antagonist with Propensity for Accumulation and Responsiveness in Ileum.
Hiroshima International University
21
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
Tes Pharma
21
Design and Structural Optimization of Dual FXR/PPARδ Activators.
Goethe University Frankfurt
13
Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists.
University of Naples "Federico Ii
24
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.
University of Naples "Federico Ii
32
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
Goethe University Frankfurt
69
Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
Dalian Medical University
26
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
Genomics Institute of The Novartis Research Foundation (Gnf)
26
Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
Chinese Academy of Sciences
1
Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
Universidad Nacional De Colombia
4
Andrographolide: A natural product template for the generation of structurally and biologically diverse diterpenes.
Institute of Higher Learning
40
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Terns Pharmaceuticals
21
Identification of potent farnesoid X receptor (FXR) antagonist showing favorable PK profile and distribution toward target tissues: Comprehensive understanding of structure-activity relationship of FXR antagonists.
Hiroshima International University
11
Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.
Wuxi Apptec (Shanghai) Co.
2
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.
Eli Lilly
3
Structure-activity relationships for lipoprotein lipase agonists that lower plasma triglycerides in vivo.
Ume£
4
Therapeutic Potential of FXR Agonists in the Treatment of Multiple Diseases.
Therachem Research Medilab
24
Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists.
Goethe-University Frankfurt
67
Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5).
Ardelyx
8
Synthesis, physicochemical properties, and biological activity of bile acids 3-glucuronides: Novel insights into bile acid signalling and detoxification.
University of Perugia
41
Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH.
Wuxi Apptec (Shanghai)
17
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
Genomics Institute of The Novartis Research Foundation
46
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
Goethe-University Frankfurt
78
MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE
Department of Health And Human Services
332
Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
Sanford Burnham Prebys Medical Discovery Institute
21
Heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and/or 2(HDAC1-2)
Medibiofarma
141
PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS
Merck Sharp &Amp
232
Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors
Array Biopharma
5
(3,4-Dihydroxyphenyl)(2,3,4-trihydroxyphenyl)methanone and its derivatives as carbonic anhydrase isoenzymes inhibitors.
Ataturk University
24
New protein farnesyltransferase inhibitors in the 3-arylthiophene 2-carboxylic acid series: diversification of the aryl moiety by solid-phase synthesis.
Centre De Recherche De Gif
13
Synthesis and SAR comparative studies of 2-allyl-4-methoxy-1-alkoxybenzenes as 15-lipoxygenase inhibitors.
Mashhad University of Medical Sciences
147
Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
Advinus Therapeutics
31
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
Cayman Chemical
27
N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals
Sanofi
1
Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
Bristol Myers Squibb
4
Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.
Abbott Laboratories
10
Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II.
Istituto Di Biostrutture E Bioimmagini-Cnr
9
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
University of Padova